Published in Int J Infect Dis on May 16, 2007
Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care (2012) 0.94
Cerebral aspergillus infection in pediatric acute lymphoblastic leukemia induction therapy. Indian J Med Paediatr Oncol (2012) 0.84
Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole. Antimicrob Agents Chemother (2009) 0.81
Successful treatment of fanconi anemia and T-cell acute lymphoblastic leukemia. Case Rep Hematol (2012) 0.81
Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins. J Fungi (Basel) (2016) 0.79
Fungal granuloma of the brain caused by Aspergillus in an adolescent boy with chronic granulomatous disease. Childs Nerv Syst (2010) 0.76
Comment on Dotis et al. "Central nervous system aspergillosis in children: a systematic review of reported cases". Int J Infect Dis (2008) 0.75
Multiple intracranial fungal abscesses in an immunocompetent infant treated surgically. J Pediatr Neurosci (2014) 0.75
Aspergillus flavus-Induced Brain Abscess in an Immunocompetent Child: Case report. Sultan Qaboos Univ Med J (2016) 0.75
Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation. Front Pediatr (2017) 0.75
Neonatal brain infections. Pediatr Radiol (2011) 0.75
Invasive aspergillosis in a patient with end stage renal disease. Med Mycol Case Rep (2017) 0.75
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J (2007) 2.25
Colistin administration to pediatric and neonatal patients. Eur J Pediatr (2010) 1.83
Parapneumonic pleural effusions caused by Streptococcus pneumoniae serotype 3 in children immunized with 13-valent conjugated pneumococcal vaccine. Pediatr Infect Dis J (2014) 1.75
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol (2010) 1.55
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Immune haemolytic anaemia due to visceral leishmaniasis in a young child. Eur J Pediatr (2003) 1.39
Fungal infections in primary immunodeficiencies. Eur J Pediatr (2007) 1.37
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother (2007) 1.36
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother (2007) 1.31
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep (2012) 1.29
Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother (2009) 1.29
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood (2005) 1.28
Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol (2005) 1.26
Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans. Infect Immun (2005) 1.24
Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus. Infect Immun (2006) 1.24
Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis (2012) 1.22
Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis (2005) 1.18
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother (2006) 1.16
Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis (2004) 1.13
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J (2012) 1.09
Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol (2008) 1.08
How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis (2012) 1.05
Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents. J Infect Dis (2010) 1.05
Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol (2005) 1.02
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother (2002) 1.01
Scedosporium apiospermum infection after near-drowning. Mycoses (2007) 1.01
Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med (2007) 0.99
Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J Antimicrob Chemother (2006) 0.98
Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr Infect Dis J (2012) 0.97
Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs (2005) 0.96
Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year. Pediatr Infect Dis J (2004) 0.95
Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses (2008) 0.95
Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother (2007) 0.95
Future directions in mucormycosis research. Clin Infect Dis (2012) 0.95
Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol (2006) 0.95
Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob Agents Chemother (2008) 0.94
Minireview: host defence in invasive aspergillosis. Mycoses (2013) 0.93
Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J (2011) 0.93
Posaconazole: when and how? The clinician's view. Mycoses (2011) 0.93
Non-Aspergillus fungal infections in chronic granulomatous disease. Mycoses (2013) 0.92
Daptomycin use in a neonate: serum level monitoring and outcome. Am J Perinatol (2009) 0.91
Acquisition of imipenem-resistant Acinetobacter baumannii in a pediatric intensive care unit: A case-control study. Intensive Care Med (2006) 0.91
Treatment and timing in invasive mould disease. J Antimicrob Chemother (2011) 0.90
Use of linezolid in pediatrics: a critical review. Int J Infect Dis (2010) 0.90
Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece. BMC Infect Dis (2009) 0.89
Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother (2010) 0.88
Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (2002) 0.88
Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob Agents Chemother (2011) 0.88
Vancomycin-resistant Enterococcus outbreak in a neonatal intensive care unit: epidemiology, molecular analysis and risk factors. Am J Infect Control (2013) 0.88
What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis? Clin Infect Dis (2013) 0.88
Outbreak of bloodstream infections because of Serratia marcescens in a pediatric department. Am J Infect Control (2012) 0.87
Seroepidemiological study of pandemic influenza H1N1 following the 2009-2010 wave in Greece. Vaccine (2011) 0.87
Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs. Infect Control Hosp Epidemiol (2006) 0.87
Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms. J Antimicrob Chemother (2010) 0.86
Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol (2007) 0.86
Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 0.86
Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol (2005) 0.85
Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol (2009) 0.85
Congenital brucellosis: a rare cause of respiratory distress in neonates. Am J Perinatol (2007) 0.84
Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother (2008) 0.84
Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2011) 0.84
Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr (2014) 0.84
Relationship between metabolism and biomass of medically important zygomycetes. Med Mycol (2006) 0.84
Life-threatening infection due to community-acquired methicillin-resistant Staphylococcus aureus: case report and review. Eur J Pediatr (2009) 0.84
Frequency, clinical characteristics, and genotype distribution of rotavirus gastroenteritis in Greece (2007-2008). J Med Virol (2011) 0.83
Trichosporon asahii: an unusual cause of invasive infection in neonates. Pediatr Infect Dis J (2002) 0.82
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother (2008) 0.82
Exserohilum infections: review of 48 cases before the 2012 United States outbreak. Med Mycol (2014) 0.82
Selective effects of interleukin (IL)-15 on antifungal activity and IL-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus species. J Infect Dis (2003) 0.82
Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother (2013) 0.82
Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury. Infect Immun (2003) 0.82
Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J (2014) 0.81
Pneumocystis pneumonia in children. Paediatr Respir Rev (2009) 0.81
Fungal biomass is a key factor affecting polymorphonuclear leucocyte-induced hyphal damage of filamentous fungi. Mycoses (2009) 0.81
Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus. Med Mycol (2010) 0.80
Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer (2011) 0.80
Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. J Antimicrob Chemother (2008) 0.80
Osteomyelitis due to Aspergillus species in chronic granulomatous disease: an update of the literature. Mycoses (2011) 0.80
Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review. Medicine (Baltimore) (2015) 0.79
Cutaneous zygomycosis in an infant with Pearson syndrome. Pediatr Blood Cancer (2008) 0.79
Brain abscesses resulting from Bacillus cereus and an Aspergillus-like mold. J Pediatr Hematol Oncol (2002) 0.79
Invasive fungal infections in children. Pediatr Infect Dis J (2009) 0.79
Diagnostic imaging of experimental invasive pulmonary aspergillosis. Med Mycol (2009) 0.79
Cytokines and fungal infections. Br J Haematol (2005) 0.79
Attitudes regarding occupational vaccines and vaccination coverage against vaccine-preventable diseases among healthcare workers working in pediatric departments in Greece. Pediatr Infect Dis J (2012) 0.79
Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses (2014) 0.78
Aspergillus and the paediatric lung. Paediatr Respir Rev (2009) 0.78
Fungal Endocarditis in Neonates: A Review of Seventy-one Cases (1971-2013). Pediatr Infect Dis J (2015) 0.78